Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16977345 | 0.91 | TLR7 (0.53) | TLR7 | |
| SCHEMBL2058420 | 0.89 | TLR7 (0.56) | TLR7NUDT1 | |
| SCHEMBL21449003 | 0.89 | TLR7 (0.56) | TLR7 | |
| SCHEMBL12175835 | 0.89 | TLR7 (0.64) | TLR7NUDT1 | |
| SCHEMBL822925 | 0.88 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL2058924 | 0.88 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL22533653 | 0.87 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL21449093 | 0.87 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL4128956 | 0.87 | TLR7 (0.61) | TLR7NUDT1 | |
| SCHEMBL12305223 | 0.87 | TLR7 (0.53) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-08-08 | — | — | US | disclosed |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-07-25 | — | — | US | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| WO-2024092067-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023280227-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-07-15 | — | — | US | disclosed |
| US-9359360-B2 | TLR agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-07 | — | — | US | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324551-A1 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1931352-A2 | TLR AGONISTS | The Regents of the University of California Office of Technology Transfer (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024707-A2 | TLR AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | TLR7 3594/4885NUDT1 4667/4885 |
| US-20090324551-A1 | TLR AGONISTS | TLR3, TLR1, TLR5 | TLR7 6/4885NUDT1 2186/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NUDT1 2487/4885 |
| US-20210213010-A1 | TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS | TLR7, TLR9, TLR8 | TLR7 1/4885NUDT1 628/4885 |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | TLR3, TLR1, TLR6 | TLR7 9/4885NUDT1 3249/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NUDT1 2487/4885 |
| US-20240261427-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NUDT1 2487/4885 |
| US-20240245796-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TLR7 3234/4885NUDT1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.